

POLICY CURES RESEARCH.

EMERGING INFECTIOUS DISEASE R&D MATRIX*

		Basic research	Drugs	Vaccines (Preventive)	Vaccines (Therapeutic)	Diagnostics	Vector control products
Filoviral diseases	Ebola	✓	✓	✓	✓	✓	✓
	Marburg	✓	✓	✓	✓	✓	✓
	Multiple / Other filoviral diseases	✓	✓	✓	✓	✓	✓
Bunyaviral diseases	Crimean Congo Haemorrhagic Fever (CCHF)	✓	✓	✓	✓	✓	✓
	Rift Valley Fever (RVF)	✓	✓	✓	✓	✓	✓
	Multiple / Other bunyaviral diseases (including Severe Fever with Thrombocytopenia Syndrome (SFTS))	✓	✓	✓	✓	✓	✓
Arenaviral haemorrhagic fevers	Lassa Fever	✓	✓	✓	✓	✓	
	Multiple / Other arenaviral haemorrhagic fevers	✓	✓	✓	✓	✓	
Coronaviral diseases	Middle East Respiratory Syndrome coronavirus (MERS-CoV)	✓	✓	✓	✓	✓	✓
	Severe Acute Respiratory Syndrome (SARS)	✓	✓	✓	✓	✓	✓
	Multiple / Other highly pathogenic coronaviral diseases	✓	✓	✓	✓	✓	
Henipaviral diseases	Nipah	✓	✓	✓	✓	✓	✓
	Multiple / Other henipaviral diseases	✓	✓	✓	✓	✓	✓
Zika		✓	✓	✓	✓	✓	✓
Multiple Emerging Infectious Diseases (EIDs)		R&D targeting multiple EID virus families (e.g. platform technologies for EIDs, multiplexed EID diagnostic assays, core funding)					

✓ denotes a category where a disease or product is included in the survey

*The survey scope for emerging infectious diseases has not been defined using the same three-step filter used to determine the G-FINDER neglected disease survey scope. All relevant R&D activities for priority pathogens identified in the WHO R&D Blueprint January 2017 review are considered in scope. The pathogens have been grouped by disease family for data collection purposes. See the [EID R&D scope document](#) for more detail.